Abstract
Mazard and colleagues present results providing evidence that sorafenib favors irinotecan intracellular accumulation and enhances irinotecan toxicity via inhibition of the drug-efflux pump ABCG2 ([1][1]). They conclude that sorafenib is a promising option for the treatment of irinotecan-resistant
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have